Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 21, 2022 | June 23, 2022 |
| ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086 | EVP, Chief Financial Officer | July 11, 2019 | July 15, 2019 |
| BIOGEN INC.BIIB · Entity 1675 | Executive VP and CFO | April 25, 2017 | April 27, 2017 |
| INCYTE CORPINCY · Entity 3182 | Director | September 30, 2026 | October 03, 2026 |
| Sionna Therapeutics, Inc.SION · Entity 5996 | Director | June 17, 2026 | June 18, 2026 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director | June 11, 2025 | June 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 21, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted stock unitSEC Table II · derivative / convertible security | Direct | 4,975 |
Reported balance
After 2022-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-21 · Grant · Acquired 4,975 · Balance 4,975 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.09 · Expires 2032-06-21 | Direct | 29,307 |
Reported balance
After 2022-06-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-21 · Grant · Acquired 29,307 · Balance 29,307 F3: This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023.
ALEXION PHARMACEUTICALS, INC.
Report date July 11, 2019 · Filed July 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 90,447 |
Reported balance
After 2019-07-11 transaction · row 1
1 source rowRow 1 · 2019-07-11 · Tax withholding · Disposed 5,230 · Balance 90,447 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
BIOGEN INC.
Report date April 25, 2017 · Filed April 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,813 |
Reported balance
After 2017-04-25 transaction · row 1
1 source rowRow 1 · 2017-04-25 · Sale · Disposed 9,892 · Balance 10,813 F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
INCYTE CORP
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,838 |
Reported balance
After 2026-09-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 203 · Balance 25,838 F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.
F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Sionna Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.73 · Expires 2036-06-16 | Direct | 17,340 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 17,340 · Balance 17,340 F1: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.
Xilio Therapeutics, Inc.
Report date June 11, 2025 · Filed June 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.69 · Expires 2035-06-10 | Direct | 31,000 |
Reported balance
After 2025-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 31,000 · Balance 31,000 F1: The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXACT SCIENCES CORP
Report date March 23, 2026 · Filed March 23, 2026
Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-23 · Disposition to issuer · Disposed 20,640 · Balance 5,398 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Row 2 · 2026-03-23 · Disposition to issuer · Disposed 5,398 · Balance 0 F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").
F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:02 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 203 | $121.35 | $24,634.05 |
DisclosureSEC source: 0001409601-26-000015 · wk-form4_1790971354.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,838 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 252 | $113.36 | $28,566.72 |
DisclosureSEC source: 0001409601-26-000011 · wk-form4_1783022882.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,635 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 21:33 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,340 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001409601-26-000010 · edgardoc.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,340 Underlying: Common Stock · 17,340 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:07 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon Qualfied Stock Option (right to buy) · Derivative | 6,111 | $0.00 Strike: $100.64 | $0.00 |
DisclosureSEC source: 0001409601-26-000008 · wk-form4_1781122071.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,111 Underlying: Common Stock · 6,111 shares Expires 2036-06-07 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:07 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001409601-26-000008 · wk-form4_1781122071.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,383 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:02 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $84.53 | $0.00 |
DisclosureSEC source: 0001409601-26-000006 · wk-form4_1779393732.xml · derivative · entry 3 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:02 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 15,000 | $94.93 | $1,423,950.00 |
DisclosureSEC source: 0001409601-26-000006 · wk-form4_1779393732.xml · nonDerivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,741 F1 · balance_after: Includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:02 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 15,000 | $84.53 | $1,267,950.00 |
DisclosureSEC source: 0001409601-26-000006 · wk-form4_1779393732.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 265 | $94.12 | $24,941.80 |
DisclosureSEC source: 0001409601-26-000004 · wk-form4_1775160591.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,741 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 5,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118743 · ownership.xml · nonDerivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 20,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118743 · ownership.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,398 F1 · price: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 241 | $98.77 | $23,803.57 |
DisclosureSEC source: 0001409601-26-000002 · wk-form4_1767647177.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,476 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:09 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 285 | $84.81 | $24,170.85 |
DisclosureSEC source: 0001409601-25-000004 · wk-form4_1759435758.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,235 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:45 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 361 | $68.10 | $24,584.10 |
DisclosureSEC source: 0000879169-25-000070 · wk-form4_1751489113.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,950 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086889 · ownership.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,038 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 21:06 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,959 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0002036042-25-000028 · edgardoc.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,959 Underlying: Common Stock · 19,959 shares Expires 2035-06-11 F1 · derivative.exercise_date: This option vests in full upon the earlier of June 12, 2026 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 20:36 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001415889-25-016968 · form4-06122025_080604.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:29 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon Qualfied Stock Option (right to buy) · Derivative | 9,216 | $0.00 Strike: $70.07 | $0.00 |
DisclosureSEC source: 0001628280-25-031006 · wk-form4_1749760138.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,216 Underlying: Common Stock · 9,216 shares Expires 2035-06-09 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:29 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-031006 · wk-form4_1749760138.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,589 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 358 | $60.55 | $21,676.90 |
DisclosureSEC source: 0001628280-25-016172 · wk-form4_1743624374.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,071 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 18:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 331 | $69.07 | $22,862.17 |
DisclosureSEC source: 0000879169-25-000004 · wk-form4_1735927599.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,713 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 17:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 368 | $66.10 | $24,324.80 |
DisclosureSEC source: 0000879169-24-000159 · wk-form4_1727888479.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,382 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 17:22 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 399 | $60.62 | $24,187.38 |
DisclosureSEC source: 0000879169-24-000102 · wk-form4_1719940951.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,014 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001415889-24-017205 · form4-06172024_040604.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,444 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074413 · ownership.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,145 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 13, 2024 Filed Dec 20, 2024 16:30 UTC Amendment | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,939 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-139097 · ownership.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,640 F1 · shares: On June 17, 2024, the Reporting Person filed a Form 4 which, due to an administrative error, incorrectly reported that the Reporting person had been awarded 5,444 shares of restricted stock pursuant to the Company's non-employee director compensation policy. This amendment to Form 4 is being filed to reflect the correct amount of shares awarded pursuant to the policy. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:13 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon Qualfied Stock Option (right to buy) · Derivative | 12,517 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0000879169-24-000091 · wk-form4_1718381589.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,517 Underlying: Common Stock · 12,517 shares Expires 2034-06-11 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:13 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,830 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000091 · wk-form4_1718381589.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,615 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| March 28, 2024 Filed Apr 2, 2024 16:12 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 403 | $56.97 | $22,958.91 |
DisclosureSEC source: 0000879169-24-000070 · wk-form4_1712074352.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,785 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,505 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 17:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 412 | $62.79 | $25,869.48 |
DisclosureSEC source: 0000879169-24-000004 · wk-form4_1704301688.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,382 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,505 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:02 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 379 | $57.77 | $21,894.83 |
DisclosureSEC source: 0000879169-23-000030 · wk-form4_1696363357.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,970 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,505 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 380 | $62.25 | $23,655.00 |
DisclosureSEC source: 0001209191-23-040943 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,591 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,505 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,294 | $0.00 Strike: $61.44 | $0.00 |
DisclosureSEC source: 0001209191-23-037795 · doc4.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,294 Underlying: Common Stock · 11,294 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037795 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,211 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001415889-23-009738 · form4-06132023_040612.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2033-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2023 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 12, 2024 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 3,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036331 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,701 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 318 | $72.27 | $22,981.86 |
DisclosureSEC source: 0001209191-23-022633 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,706 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:02 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 294 | $80.32 | $23,614.08 |
DisclosureSEC source: 0001209191-23-000806 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,388 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 339 | $66.64 | $22,590.96 |
DisclosureSEC source: 0001209191-22-052162 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,094 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 321 | $75.97 | $24,386.37 |
DisclosureSEC source: 0001209191-22-040183 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,755 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 29,307 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001439222-22-000061 · wf-form4_165601496361572.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,307 Underlying: Common stock · 29,307 shares Expires 2032-06-21 F3 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock unit · Derivative | 4,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000061 · wf-form4_165601496361572.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,975 Underlying: Common stock · 4,975 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,124 | $0.00 Strike: $68.55 | $0.00 |
DisclosureSEC source: 0001209191-22-037801 · doc4.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,124 Underlying: Common Stock · 9,124 shares Expires 2032-06-14 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,144 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037801 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,434 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001415889-22-006744 · form4-06172022_040611.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option award was granted on June 15, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 15, 2023 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 17:25 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036409 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,102 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock unit · Derivative | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000054 · wf-form4_165342316015735.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000054 · wf-form4_165342316015735.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 326 | $79.42 | $25,890.92 |
DisclosureSEC source: 0001209191-22-022282 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,290 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:14 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 343 | $73.40 | $25,176.20 |
DisclosureSEC source: 0001209191-22-000690 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,964 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.